AU2008317374B2 - Competitive inhibitors of invariant chain expression and/or ectopic clip binding - Google Patents

Competitive inhibitors of invariant chain expression and/or ectopic clip binding Download PDF

Info

Publication number
AU2008317374B2
AU2008317374B2 AU2008317374A AU2008317374A AU2008317374B2 AU 2008317374 B2 AU2008317374 B2 AU 2008317374B2 AU 2008317374 A AU2008317374 A AU 2008317374A AU 2008317374 A AU2008317374 A AU 2008317374A AU 2008317374 B2 AU2008317374 B2 AU 2008317374B2
Authority
AU
Australia
Prior art keywords
peptide
clip
cell
subject
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008317374A
Other languages
English (en)
Other versions
AU2008317374A1 (en
Inventor
Evan Newell
Martha Karen Newell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
Original Assignee
University of Colorado Boulder
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder, University of Colorado System filed Critical University of Colorado Boulder
Publication of AU2008317374A1 publication Critical patent/AU2008317374A1/en
Application granted granted Critical
Publication of AU2008317374B2 publication Critical patent/AU2008317374B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Computing Systems (AREA)
  • Library & Information Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2008317374A 2007-10-23 2008-10-23 Competitive inhibitors of invariant chain expression and/or ectopic clip binding Ceased AU2008317374B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15207P 2007-10-23 2007-10-23
US61/000,152 2007-10-23
US13596408P 2008-07-25 2008-07-25
US13715008P 2008-07-25 2008-07-25
US61/137,150 2008-07-25
US61/135,964 2008-07-25
PCT/US2008/012078 WO2009055005A2 (en) 2007-10-23 2008-10-23 Competitive inhibitors of invariant chain expression and/or ectopic clip binding

Publications (2)

Publication Number Publication Date
AU2008317374A1 AU2008317374A1 (en) 2009-04-30
AU2008317374B2 true AU2008317374B2 (en) 2015-03-19

Family

ID=40580294

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008317374A Ceased AU2008317374B2 (en) 2007-10-23 2008-10-23 Competitive inhibitors of invariant chain expression and/or ectopic clip binding

Country Status (6)

Country Link
US (4) US8957031B2 (enExample)
EP (1) EP2215108A4 (enExample)
JP (1) JP2011502964A (enExample)
AU (1) AU2008317374B2 (enExample)
CA (1) CA2703585A1 (enExample)
WO (1) WO2009055005A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008211199A1 (en) * 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function
US8957031B2 (en) 2007-10-23 2015-02-17 Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
CA2736842A1 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Proteins for use in diagnosing and treating infection and disease
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
EP2323679A4 (en) * 2008-07-25 2012-08-22 Univ Colorado CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
CA2860768A1 (en) 2011-01-05 2013-07-12 The Texas A&M University System Clip modulation for the treatment of mucosal diseases
WO2012138708A1 (en) * 2011-04-04 2012-10-11 The Texas A&M University System Mhc engagement and clip modulation for the treatment of disease
US9359404B2 (en) 2011-12-01 2016-06-07 Scott & White Healthcare Methods and products for treating preeclampsia and modulating blood pressure
WO2015035414A1 (en) * 2013-09-09 2015-03-12 The Texas A&M University System Treating neurological disorders
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
US20170177802A1 (en) * 2015-12-17 2017-06-22 Allergy Solutions, Inc. Allergy Service Management Portal
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
WO2019055860A1 (en) * 2017-09-15 2019-03-21 The Texas A&M University System METHODS FOR IMPROVING IMMUNOTHERAPY IN THE TREATMENT OF CANCER
US12458411B2 (en) 2017-12-07 2025-11-04 Augmedics Ltd. Spinous process clamp
US12521201B2 (en) 2017-12-07 2026-01-13 Augmedics Ltd. Spinous process clamp
EP3517117A1 (en) * 2018-01-30 2019-07-31 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection
WO2019211741A1 (en) 2018-05-02 2019-11-07 Augmedics Ltd. Registration of a fiducial marker for an augmented reality system
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
CN110033822B (zh) * 2019-03-29 2020-12-08 华中科技大学 蛋白质编码方法及蛋白质翻译后修饰位点预测方法及系统
TWI747121B (zh) * 2019-05-21 2021-11-21 大江生醫股份有限公司 茶樹葉的發酵物用於調控ＣＣＴ基因、Ｐｉｎｋ１基因、ＰＡＲＰ２基因、ＭＩＴＦ基因、ＵＮＧ基因、ＥＲＣＣ６基因、ＴＥＲＣ基因、ＣＤ４０基因、ＤＹＮＬＬ２基因、ＧＲＫ５基因、ＲＥＬＢ基因、ＴＮＦＳＦ１４基因、ＩＬ４Ｒ基因與ＲＥＬＡ基因的表現量及抗老化、美白、提升免疫力與降低脂肪累積之用途
CN110296833B (zh) * 2019-07-22 2020-08-18 齐鲁工业大学 一种面向液压缸综合测试台的软测量方法及系统
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US12178666B2 (en) 2019-07-29 2024-12-31 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
IL298410A (en) * 2020-05-22 2023-01-01 Alberto Riveros Carlos System, method and use of certain drugs for reducing viral replication in respiratory tract mucosa
US11389252B2 (en) 2020-06-15 2022-07-19 Augmedics Ltd. Rotating marker for image guided surgery
US12239385B2 (en) 2020-09-09 2025-03-04 Augmedics Ltd. Universal tool adapter
US12502163B2 (en) 2020-09-09 2025-12-23 Augmedics Ltd. Universal tool adapter for image-guided surgery
US20220293228A1 (en) * 2021-03-09 2022-09-15 Glenn Loomis Identification of Allergens in Food Products
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
US12150821B2 (en) 2021-07-29 2024-11-26 Augmedics Ltd. Rotating marker and adapter for image-guided surgery
US12475662B2 (en) 2021-08-18 2025-11-18 Augmedics Ltd. Stereoscopic display and digital loupe for augmented-reality near-eye display
WO2023203521A1 (en) 2022-04-21 2023-10-26 Augmedics Ltd. Systems and methods for medical image visualization
IL319523A (en) 2022-09-13 2025-05-01 Augmedics Ltd Augmented reality glasses for image-guided medical intervention

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025344A1 (en) * 1996-01-03 1997-07-17 The Australian National University Clip analogues and autoimmune disease
WO2008094510A2 (en) * 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415553A (en) 1973-08-06 1983-11-15 Dso "Pharmachim" Compositions, processes for their preparation and method for treatment of neoplasms
EP0149468B1 (de) * 1984-01-12 1990-10-31 SYMBIOTEC Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie GmbH Biologisch wirksame Substanz mit hormonellen Eigenschaften, Verfahren zu ihrer Herstellung und Verwendung von Histonen für medizinische Zwecke
DE3588239T3 (de) * 1985-03-30 2007-03-08 Kauffman, Stuart A., Santa Fe Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
ATE213162T1 (de) * 1992-03-13 2002-02-15 Terry R Beardsley Thymus-stammendes, immunverstärkendes agens zur therapeutischen verwendung in einem wirt mit einem angegriffenen immunsystem
US20050271676A1 (en) * 1993-03-05 2005-12-08 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
WO1995011255A1 (en) * 1993-10-19 1995-04-27 Ajinomoto Co., Inc. Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
JP3816524B2 (ja) 1995-05-01 2006-08-30 トムソン．ユー．エス．エー．リミテッド． 後天性免疫不全症候群を検出しそして処置するための組成物および方法
US7625565B2 (en) * 1995-05-01 2009-12-01 Viral Genetics, Inc. Antiviral compositions comprising lysine-rich histone fractions prepared by pepsin treatment of thymic cell nuclei
AU7690896A (en) * 1995-09-14 1997-04-01 Universitat Tubingen Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific t-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide
US20060008448A1 (en) * 1996-06-11 2006-01-12 Minzhen Xu Inhibition of li expression in mammalian cells
WO1998018491A1 (en) 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation
AU6336398A (en) * 1997-02-24 1998-09-09 Johns Hopkins University, The Immunomodulatory polypeptides derived from the invariant chain of mhc class ii
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6165493A (en) * 1997-10-22 2000-12-26 New York Blood Center, Inc. "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
US6734192B1 (en) * 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US20020164685A1 (en) * 2000-01-31 2002-11-07 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
AU2002327338A1 (en) 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CN1458165A (zh) 2002-01-26 2003-11-26 北海新升技术开发有限责任公司 一种多肽类物质及其制备方法和用途
FR2836483B1 (fr) * 2002-02-22 2006-09-15 Innate Pharma Procedes de production de lymphocytes gamma delta t
ATE477276T1 (de) 2002-03-01 2010-08-15 Immunomedics Inc Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
JP2006515577A (ja) 2002-09-23 2006-06-01 ザ・チャンセラー，マスターズ・アンド・スカラーズ・オヴ・ザ・ユニヴァーシティ・オヴ・オックスフォード イオンチャネル活性を阻害するためのイミノ糖誘導体の使用
EP2364716A3 (en) 2002-11-08 2012-01-11 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
CA2525778A1 (en) * 2003-05-14 2004-12-23 Siga Technologies, Inc. T cell epitopes useful in a severe acute respiratory syndrome (sars) virus vaccine and as diagnostic tools and methods for identifying same
EP1638993A4 (en) 2003-06-10 2007-05-09 Univ Melbourne IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
US7812116B2 (en) * 2003-07-03 2010-10-12 Rush University Medical Center Immunogenic peptides
US8101714B2 (en) 2004-02-18 2012-01-24 The University Of Georgia Research Foundation, Inc. Teleost derived antimicrobial polypeptides
WO2006114799A1 (en) * 2005-04-27 2006-11-02 Universita' Degli Studi Di Roma 'tor Vergata' Synthetic peptides for the diagnosis and therapy of berillium granulomatous disease
US20080094510A1 (en) * 2005-08-05 2008-04-24 Samsung Electronics Co., Ltd. Apparatus for providing multiple screens and method of dynamically configuring multiple screens
WO2007091240A2 (en) 2006-02-06 2007-08-16 Immune System Key Ltd. Treatment of immunological diseases
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
US20090291884A1 (en) 2006-11-02 2009-11-26 Michael Agadjanyan Proteins for use in diagnosing and treating infection and disease
US8957031B2 (en) 2007-10-23 2015-02-17 Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
CA2730773A1 (en) * 2008-07-14 2010-01-21 Martha Karen Newell Methods and products for treating proliferative diseases
EP2323681A4 (en) * 2008-07-25 2012-11-14 Univ Colorado METHOD FOR TREATING VIRAL DISEASES
CA2736842A1 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Proteins for use in diagnosing and treating infection and disease
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
CA2860768A1 (en) * 2011-01-05 2013-07-12 The Texas A&M University System Clip modulation for the treatment of mucosal diseases
WO2012138708A1 (en) * 2011-04-04 2012-10-11 The Texas A&M University System Mhc engagement and clip modulation for the treatment of disease
US9359404B2 (en) * 2011-12-01 2016-06-07 Scott & White Healthcare Methods and products for treating preeclampsia and modulating blood pressure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025344A1 (en) * 1996-01-03 1997-07-17 The Australian National University Clip analogues and autoimmune disease
WO2008094510A2 (en) * 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function

Also Published As

Publication number Publication date
US20170348377A1 (en) 2017-12-07
US10420813B2 (en) 2019-09-24
EP2215108A2 (en) 2010-08-11
US20200069766A1 (en) 2020-03-05
WO2009055005A2 (en) 2009-04-30
US8957031B2 (en) 2015-02-17
EP2215108A4 (en) 2012-07-04
CA2703585A1 (en) 2009-04-30
US20150231195A1 (en) 2015-08-20
US20110118175A1 (en) 2011-05-19
JP2011502964A (ja) 2011-01-27
AU2008317374A1 (en) 2009-04-30
WO2009055005A9 (en) 2009-09-24
WO2009055005A3 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
AU2008317374B2 (en) Competitive inhibitors of invariant chain expression and/or ectopic clip binding
US20100166789A1 (en) Proteins for use in diagnosing and treating infection and disease
US20130259829A1 (en) Clip inhibitors and methods of modulating immune function
US20100034839A1 (en) Methods for treating viral disorders
Morikis et al. Solution structure of Compstatin, a potent complement inhibitor
EA015584B1 (ru) Антитело к cd38 человека и его применение
EP2633864A1 (en) Clip inhibitors and methods of modulating immune function
Webb et al. T cell determinants incorporating β-amino acid residues are protease resistant and remain immunogenic in vivo
US6337316B1 (en) Pharmaceutical compositions thereof, and methods of using same
US20140220000A1 (en) Mhc engagement and clip modulation for the treatment of disease
US20230226135A9 (en) Acetylcholine modulation of immune function
CN107124883A (zh) 具有破骨细胞分化及活性抑制能力的肽及其用途
WO2021113311A9 (en) Treatment of cancer using acetylcholine modulation and immunotherapy
WO2024013330A1 (en) Immunogenic personalised cancer vaccines
EP4306125A1 (en) Immunogenic personalised cancer vaccines
US20250339503A1 (en) Peptides and combinations of peptides for use in immunotherapy against acute myeloid leukemia (aml) and other hematological neoplasms
WO2022140180A1 (en) Methods and products for treating kidney disease
Zavala-Ruiz Structure studies of the human class II major histocompatibility complex protein HLA-DR1
Manual Emapalumab-LZSG (eg, Gamifant)
UA96922U (uk) Спосіб підвищення впевненості у спортсменів

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired